BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

By N. Watanabe, Maya Gavrieli, J. Šedý, Jianfei Yang, Francesca Fallarino, S. Loftin, Michelle A. Hurchla, N. Zimmerman, Julia Sim, X. Zang and 4 more. Nature Immunology, 2003

902 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/0da1c86e6d3b1323f0556ff64e4a86d5ad17ad18

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Inhibitory B7-family molecules in the tumour microenvironment (2008, background): “B- and T-lymphocyte attenuator (BTLA) was initially proposed to be the receptor for B7-H4 (Ref”
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator (2005, neutral): “dtd" [ ]> The lymphoid-specific cell surface receptor B and T lymphocyte attenuator (BTLA) inhibits lymphocytes during immune response”
PD-1 signaling in primary T cells (2009, background): “B- and T-lymphocyte attenuator (BTLA), the most recently described member of the CD28 family (22), shares many features with PD-1 and may also be considered a CD28 family outlier.”
Immunosuppressive strategies that are mediated by tumor cells. (2007, background): “N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript In this regard, Watanabe and colleagues identified a third inhibitory receptor on T-cells: “the B- and T-lymphocyte attenuator (BTLA)” with similarities to CTLA-4 and PD-1 (94).”
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (2004, background): “The repertoire of negative regulators expressed on T lymphocytes has increased in scope and complexity with the recent delineation of B- and T-lymphocyte attenuator (68) and a further as-yet-unidentified molecule bound by B7-H3 (62).”
Mechanisms of immune evasion by tumors. (2006, background): “Murphy and colleagues, have recently described a new member of the coinhibitor group of molecules, which they coined BTLA (B and T lymphocyte attenuator) (Watanabe et al., 2003).”
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells (2004, background): “In addition, the recently described inhibitory receptor BTLA that has functional similarities to PD-1 appears to recognize the B7 family member B7x (39, 40) that also could be expressed by tumor cells.”
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy (2005, background): “The fact that PD-L1/PD-1 engagement can attenuate ICOS-positive costimulatory signals [5], that its negative signaling however can be negated by CD28 ligation or IL-2 [12], and the identification of a further negative regulatory receptor, BTLA [11, 75], indicates that the overall result from negativ”
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity (2004, background): “BTLA was recently identified as an immunoglobulin-superfamily member with limited homology to CTLA4 (Ref”
The blockade of immune checkpoints in cancer immunotherapy (2012, background): “BTLA was first identified as an inhibitory receptor on T cells on the basis of the enhanced T cell responses that were observed in Btla -knockout mic”